Nair Sreelakshmi R, Subathra Devi C
Department of Biotechnology, School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Front Microbiol. 2024 May 9;15:1382816. doi: 10.3389/fmicb.2024.1382816. eCollection 2024.
Anti-inflammatory enzymes have wide applications in the pharmaceutical industry. The objective of this study was to find new and efficient strains for the commercial production of serratiopeptidase enzyme. Vast number of samples were processed for the isolation of potent strains. The experimental treatment includes processing of twenty soil samples, silkworm gut, and sugarcane stem. The total protein and protease activity was estimated by Lowry's method and casein hydrolysis. The HRBC stabilization assay was performed for finding the anti-inflammatory potential of all strains. The serratiopeptidase production was confirmed by HPLC with the standard. Molecular characterization of selected potent strains was done by 16S rDNA and confirmed the taxonomy. The one step rapid purification of serratiopeptidase was performed by Ultra three phase partitioning method. The clot lysis potential of the VS56 was observed by modified Holmstorm method. The results of the study revealed that among the 60 strains, 12 strains were protease-positive on skim milk agar plates and showed significant protease activity. All 12 strains were screened for serratiopeptidase using high-performance liquid chromatography (HPLC) and VS56, VS10, VS12 and VS18 showed a similar retention time (4.66 ± 0.10 min) with standard. The selected potent strain, VS56 showed a proteolytic activity of 21.30 units/mL and produced a total protein of 102 mg/mL. The HRBC suspension results also showed a percentage of 94.6 ± 1.00 protection, which was compared to the standard diclofenac. The clot lysis potential of VS56 was 53% in 4 h. Furthermore, the molecular weight of the protein was identified to confirm the presence of serratiopeptidase. The study hence contributed successfully to isolating, screening, and identifying a potent producer for serratiopeptidase from an environmental source. This inherent advantage of the strain will undoubtedly contribute much to the coco comm commercial production of serratiopeptidase in the near future.
抗炎酶在制药行业有广泛应用。本研究的目的是寻找用于商业生产沙雷氏菌蛋白酶的新型高效菌株。处理了大量样本以分离出高效菌株。实验处理包括对二十个土壤样本、蚕肠道和甘蔗茎进行处理。通过洛瑞法和酪蛋白水解来估算总蛋白和蛋白酶活性。进行人红细胞稳定试验以测定所有菌株的抗炎潜力。通过高效液相色谱法(HPLC)与标准品对照来确认沙雷氏菌蛋白酶的产生。通过16S rDNA对所选高效菌株进行分子表征并确定其分类学地位。采用超三相分配法对沙雷氏菌蛋白酶进行一步快速纯化。通过改良的霍尔姆斯特伦法观察VS56的凝块溶解潜力。研究结果表明,在60株菌株中,有12株在脱脂乳琼脂平板上蛋白酶呈阳性,并表现出显著的蛋白酶活性。使用高效液相色谱法(HPLC)对所有12株菌株进行沙雷氏菌蛋白酶筛选,VS56、VS10、VS12和VS18与标准品显示出相似的保留时间(4.66±0.10分钟)。所选高效菌株VS56的蛋白水解活性为21.30单位/毫升,总蛋白产量为102毫克/毫升。人红细胞悬浮液结果还显示与标准双氯芬酸相比有94.6±1.00%的保护率。VS56在4小时内的凝块溶解潜力为53%。此外,鉴定了该蛋白的分子量以确认沙雷氏菌蛋白酶的存在。因此,该研究成功地从环境来源中分离、筛选并鉴定出了一种高效的沙雷氏菌蛋白酶生产者。该菌株的这一固有优势无疑将在不久的将来对沙雷氏菌蛋白酶的商业生产有很大贡献。